Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 242

1.

The evolutionary history of 2,658 cancers.

Gerstung M, Jolly C, Leshchiner I, Dentro SC, Gonzalez S, Rosebrock D, Mitchell TJ, Rubanova Y, Anur P, Yu K, Tarabichi M, Deshwar A, Wintersinger J, Kleinheinz K, Vázquez-García I, Haase K, Jerman L, Sengupta S, Macintyre G, Malikic S, Donmez N, Livitz DG, Cmero M, Demeulemeester J, Schumacher S, Fan Y, Yao X, Lee J, Schlesner M, Boutros PC, Bowtell DD, Zhu H, Getz G, Imielinski M, Beroukhim R, Sahinalp SC, Ji Y, Peifer M, Markowetz F, Mustonen V, Yuan K, Wang W, Morris QD; PCAWG Evolution & Heterogeneity Working Group, Spellman PT, Wedge DC, Van Loo P; PCAWG Consortium.

Nature. 2020 Feb;578(7793):122-128. doi: 10.1038/s41586-019-1907-7. Epub 2020 Feb 6.

PMID:
32025013
2.

Integrative pathway enrichment analysis of multivariate omics data.

Paczkowska M, Barenboim J, Sintupisut N, Fox NS, Zhu H, Abd-Rabbo D, Mee MW, Boutros PC; PCAWG Drivers and Functional Interpretation Working Group, Reimand J; PCAWG Consortium.

Nat Commun. 2020 Feb 5;11(1):735. doi: 10.1038/s41467-019-13983-9.

3.

Divergent mutational processes distinguish hypoxic and normoxic tumours.

Bhandari V, Li CH, Bristow RG, Boutros PC; PCAWG Consortium.

Nat Commun. 2020 Feb 5;11(1):737. doi: 10.1038/s41467-019-14052-x.

4.

Noncoding mutations target cis-regulatory elements of the FOXA1 plexus in prostate cancer.

Zhou S, Hawley JR, Soares F, Grillo G, Teng M, Madani Tonekaboni SA, Hua JT, Kron KJ, Mazrooei P, Ahmed M, Arlidge C, Yun HY, Livingstone J, Huang V, Yamaguchi TN, Espiritu SMG, Zhu Y, Severson TM, Murison A, Cameron S, Zwart W, van der Kwast T, Pugh TJ, Fraser M, Boutros PC, Bristow RG, He HH, Lupien M.

Nat Commun. 2020 Jan 23;11(1):441. doi: 10.1038/s41467-020-14318-9.

5.

Candidate Cancer Driver Mutations in Distal Regulatory Elements and Long-Range Chromatin Interaction Networks.

Zhu H, Uusküla-Reimand L, Isaev K, Wadi L, Alizada A, Shuai S, Huang V, Aduluso-Nwaobasi D, Paczkowska M, Abd-Rabbo D, Ocsenas O, Liang M, Thompson JD, Li Y, Ruan L, Krassowski M, Dzneladze I, Simpson JT, Lupien M, Stein LD, Boutros PC, Wilson MD, Reimand J.

Mol Cell. 2020 Jan 17. pii: S1097-2765(19)30957-8. doi: 10.1016/j.molcel.2019.12.027. [Epub ahead of print]

PMID:
31954095
6.

A community effort to create standards for evaluating tumor subclonal reconstruction.

Salcedo A, Tarabichi M, Espiritu SMG, Deshwar AG, David M, Wilson NM, Dentro S, Wintersinger JA, Liu LY, Ko M, Sivanandan S, Zhang H, Zhu K, Ou Yang TH, Chilton JM, Buchanan A, Lalansingh CM, P'ng C, Anghel CV, Umar I, Lo B, Zou W; DREAM SMC-Het Participants, Simpson JT, Stuart JM, Anastassiou D, Guan Y, Ewing AD, Ellrott K, Wedge DC, Morris Q, Van Loo P, Boutros PC.

Nat Biotechnol. 2020 Jan;38(1):97-107. doi: 10.1038/s41587-019-0364-z. Epub 2020 Jan 9.

PMID:
31919445
7.

Optimization and expansion of non-negative matrix factorization.

Lin X, Boutros PC.

BMC Bioinformatics. 2020 Jan 6;21(1):7. doi: 10.1186/s12859-019-3312-5.

8.

miR-191 promotes radiation resistance of prostate cancer through interaction with RXRA.

Ray J, Haughey C, Hoey C, Jeon J, Murphy R, Dura-Perez L, McCabe N, Downes M, Jain S, Boutros PC, Mills IG, Liu SK.

Cancer Lett. 2020 Mar 31;473:107-117. doi: 10.1016/j.canlet.2019.12.025. Epub 2019 Dec 23.

9.

Spleen tyrosine kinase expression is correlated with human papillomavirus in head and neck cancer.

Black M, Ghasemi F, Sun RX, Stecho W, Datti A, Meens J, Pinto N, Ruicci KM, Khan MI, Han MW, Shaikh M, Yoo J, Fung K, MacNeil D, Palma DA, Winquist E, Howlett CJ, Mymryk JS, Ailles L, Boutros PC, Barrett JW, Nichols AC.

Oral Oncol. 2020 Feb;101:104529. doi: 10.1016/j.oraloncology.2019.104529. Epub 2019 Dec 19.

PMID:
31864959
10.

A transcriptome-based signature of pathological angiogenesis predicts breast cancer patient survival.

Guarischi-Sousa R, Monteiro JS, Alecrim LC, Michaloski JS, Cardeal LB, Ferreira EN, Carraro DM, Nunes DN, Dias-Neto E, Reimand J, Boutros PC, Setubal JC, Giordano RJ.

PLoS Genet. 2019 Dec 17;15(12):e1008482. doi: 10.1371/journal.pgen.1008482. eCollection 2019 Dec.

11.

Genomic and human papillomavirus profiling of an oral cancer cohort identifies TP53 as a predictor of overall survival.

Mundi N, Prokopec SD, Ghasemi F, Warner A, Patel K, MacNeil D, Howlett C, Stecho W, Plantinga P, Pinto N, Ruicci KM, Khan MI, Han MW, Yoo J, Fung K, Sahovaler A, Palma DA, Winquist E, Mymryk JS, Barrett JW, Boutros PC, Nichols AC.

Cancers Head Neck. 2019 Dec 5;4:5. doi: 10.1186/s41199-019-0045-0. eCollection 2019.

12.

The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact.

van Dessel LF, van Riet J, Smits M, Zhu Y, Hamberg P, van der Heijden MS, Bergman AM, van Oort IM, de Wit R, Voest EE, Steeghs N, Yamaguchi TN, Livingstone J, Boutros PC, Martens JWM, Sleijfer S, Cuppen E, Zwart W, van de Werken HJG, Mehra N, Lolkema MP.

Nat Commun. 2019 Nov 20;10(1):5251. doi: 10.1038/s41467-019-13084-7.

13.

Cistrome Partitioning Reveals Convergence of Somatic Mutations and Risk Variants on Master Transcription Regulators in Primary Prostate Tumors.

Mazrooei P, Kron KJ, Zhu Y, Zhou S, Grillo G, Mehdi T, Ahmed M, Severson TM, Guilhamon P, Armstrong NS, Huang V, Yamaguchi TN, Fraser M, van der Kwast T, Boutros PC, He HH, Bergman AM, Bristow RG, Zwart W, Lupien M.

Cancer Cell. 2019 Dec 9;36(6):674-689.e6. doi: 10.1016/j.ccell.2019.10.005. Epub 2019 Nov 14.

PMID:
31735626
14.

Local Failure and Survival After Definitive Radiotherapy for Aggressive Prostate Cancer: An Individual Patient-level Meta-analysis of Six Randomized Trials.

Kishan AU, Chu FI, King CR, Seiferheld W, Spratt DE, Tran P, Wang X, Pugh SE, Sandler KA, Bolla M, Maingon P, De Reijke T, Nickols NG, Rettig M, Drakaki A, Liu ST, Reiter RE, Chang AJ, Feng FY, Sajed D, Nguyen PL, Kupelian PA, Steinberg ML, Boutros PC, Elashoff D, Collette L, Sandler HM.

Eur Urol. 2020 Feb;77(2):201-208. doi: 10.1016/j.eururo.2019.10.008. Epub 2019 Nov 10.

PMID:
31718822
15.

Genome-wide germline correlates of the epigenetic landscape of prostate cancer.

Houlahan KE, Shiah YJ, Gusev A, Yuan J, Ahmed M, Shetty A, Ramanand SG, Yao CQ, Bell C, O'Connor E, Huang V, Fraser M, Heisler LE, Livingstone J, Yamaguchi TN, Rouette A, Foucal A, Espiritu SMG, Sinha A, Sam M, Timms L, Johns J, Wong A, Murison A, Orain M, Picard V, Hovington H, Bergeron A, Lacombe L, Lupien M, Fradet Y, Têtu B, McPherson JD, Pasaniuc B, Kislinger T, Chua MLK, Pomerantz MM, van der Kwast T, Freedman ML, Mani RS, He HH, Bristow RG, Boutros PC.

Nat Med. 2019 Oct;25(10):1615-1626. doi: 10.1038/s41591-019-0579-z. Epub 2019 Oct 7.

PMID:
31591588
16.

Rethinking Lupus Nephritis Classification on a Molecular Level.

Almaani S, Prokopec SD, Zhang J, Yu L, Avila-Casado C, Wither J, Scholey JW, Alberton V, Malvar A, Parikh SV, Boutros PC, Rovin BH, Reich HN.

J Clin Med. 2019 Sep 23;8(10). pii: E1524. doi: 10.3390/jcm8101524.

17.

Comparative toxicoproteogenomics of mouse and rat liver identifies TCDD-resistance genes.

Prokopec SD, Lu A, Lee SCS, Yao CQ, Sun RX, Watson JD, Soliymani R, de Borja R, Wong A, Sam M, Zuzarte P, McPherson JD, Okey AB, Pohjanvirta R, Boutros PC.

Arch Toxicol. 2019 Oct;93(10):2961-2978. doi: 10.1007/s00204-019-02560-0. Epub 2019 Sep 11.

PMID:
31511937
18.

Reproducible biomedical benchmarking in the cloud: lessons from crowd-sourced data challenges.

Ellrott K, Buchanan A, Creason A, Mason M, Schaffter T, Hoff B, Eddy J, Chilton JM, Yu T, Stuart JM, Saez-Rodriguez J, Stolovitzky G, Boutros PC, Guinney J.

Genome Biol. 2019 Sep 10;20(1):195. doi: 10.1186/s13059-019-1794-0.

19.

A three-gene DNA methylation biomarker accurately classifies early stage prostate cancer.

Patel PG, Wessel T, Kawashima A, Okello JBA, Jamaspishvili T, Guérard KP, Lee L, Lee AY, How NE, Dion D, Scarlata E, Jackson CL, Boursalie S, Sack T, Dunn R, Moussa M, Mackie/ K, Ellis A, Marra E, Chin J, Siddiqui K, Hetou K, Pickard LA, Arthur-Hayward V, Bauman G, Chevalier S, Brimo F, Boutros PC, Lapointe PhD J, Bartlett JMS, Gooding RJ, Berman DM.

Prostate. 2019 Oct;79(14):1705-1714. doi: 10.1002/pros.23895. Epub 2019 Aug 21.

PMID:
31433512
20.

2,3,7,8-Tetrachlorodibenzo-p-dioxin modifies alternative splicing in mouse liver.

Villaseñor-Altamirano AB, Watson JD, Prokopec SD, Yao CQ, Boutros PC, Pohjanvirta R, Valdés-Flores J, Elizondo G.

PLoS One. 2019 Aug 6;14(8):e0219747. doi: 10.1371/journal.pone.0219747. eCollection 2019.

21.

Modelling the MYC-driven normal-to-tumour switch in breast cancer.

Lourenco C, Kalkat M, Houlahan KE, De Melo J, Longo J, Done SJ, Boutros PC, Penn LZ.

Dis Model Mech. 2019 Jul 26;12(7). pii: dmm038083. doi: 10.1242/dmm.038083.

22.

MicroRNA‑198 suppresses prostate tumorigenesis by targeting MIB1.

Ray J, Hoey C, Huang X, Jeon J, Taeb S, Downes MR, Boutros PC, Liu SK.

Oncol Rep. 2019 Sep;42(3):1047-1056. doi: 10.3892/or.2019.7234. Epub 2019 Jul 15.

23.

Landscape of transcriptomic interactions between breast cancer and its microenvironment.

Fox NS, Haider S, Harris AL, Boutros PC.

Nat Commun. 2019 Jul 15;10(1):3116. doi: 10.1038/s41467-019-10929-z.

24.

Temporal stability and prognostic biomarker potential of the prostate cancer urine transcriptome.

Jeon J, Olkhov-Mitsel E, Xie H, Yao CQ, Zhao F, Jahangiri S, Cuizon C, Scarcello S, Jeyapala R, Watson JD, Fraser M, Ray J, Commisso K, Loblaw A, Fleshner NE, Bristow RG, Downes M, Vesprini D, Liu S, Bapat B, Boutros PC.

J Natl Cancer Inst. 2019 Jun 4. pii: djz112. doi: 10.1093/jnci/djz112. [Epub ahead of print]

PMID:
31161221
25.

Mesenchyme to epithelial transition protein expression, gene copy number and clinical outcome in a large non-small cell lung cancer surgical cohort.

Rivalland G, Mitchell P, Murone C, Asadi K, Morey AL, Starmans M, Boutros PC, Walkiewicz M, Solomon B, Wright G, Knight S, John T.

Transl Lung Cancer Res. 2019 Apr;8(2):167-175. doi: 10.21037/tlcr.2019.03.11.

26.

PDGFRα+ stromal adipocyte progenitors transition into epithelial cells during lobulo-alveologenesis in the murine mammary gland.

Joshi PA, Waterhouse PD, Kasaian K, Fang H, Gulyaeva O, Sul HS, Boutros PC, Khokha R.

Nat Commun. 2019 Apr 15;10(1):1760. doi: 10.1038/s41467-019-09748-z.

27.

RSPO3 is a prognostic biomarker and mediator of invasiveness in prostate cancer.

Mesci A, Lucien F, Huang X, Wang EH, Shin D, Meringer M, Hoey C, Ray J, Boutros PC, Leong HS, Liu SK.

J Transl Med. 2019 Apr 15;17(1):125. doi: 10.1186/s12967-019-1878-3.

28.

Author Correction: Best practices for benchmarking germline small-variant calls in human genomes.

Krusche P, Trigg L, Boutros PC, Mason CE, De La Vega FM, Moore BL, Gonzalez-Porta M, Eberle MA, Tezak Z, Lababidi S, Truty R, Asimenos G, Funke B, Fleharty M, Chapman BA, Salit M, Zook JM; Global Alliance for Genomics and Health Benchmarking Team.

Nat Biotechnol. 2019 May;37(5):567. doi: 10.1038/s41587-019-0108-0.

PMID:
30899106
29.

Transcriptomic Impact of IMA-08401, a Novel AHR Agonist Resembling Laquinimod, on Rat Liver.

Prokopec SD, Pohjanvirta R, Mahiout S, Pettersson L, Boutros PC.

Int J Mol Sci. 2019 Mar 19;20(6). pii: E1370. doi: 10.3390/ijms20061370.

30.

The Proteogenomic Landscape of Curable Prostate Cancer.

Sinha A, Huang V, Livingstone J, Wang J, Fox NS, Kurganovs N, Ignatchenko V, Fritsch K, Donmez N, Heisler LE, Shiah YJ, Yao CQ, Alfaro JA, Volik S, Lapuk A, Fraser M, Kron K, Murison A, Lupien M, Sahinalp C, Collins CC, Tetu B, Masoomian M, Berman DM, van der Kwast T, Bristow RG, Kislinger T, Boutros PC.

Cancer Cell. 2019 Mar 18;35(3):414-427.e6. doi: 10.1016/j.ccell.2019.02.005.

PMID:
30889379
31.

A readout of metabolic efficiency in arylamine N-acetyltransferase-deficient mice reveals minor energy metabolism changes.

Denis RGP, Busi F, Castel J, Morel C, Zhang W, Bui LC, Sugamori KS, Prokopec SD, Boutros PC, Grant DM, Rodrigues-Lima F, Luquet S, Dupret JM.

FEBS Lett. 2019 Apr;593(8):831-841. doi: 10.1002/1873-3468.13357. Epub 2019 Mar 22.

PMID:
30883722
32.

Best practices for benchmarking germline small-variant calls in human genomes.

Krusche P, Trigg L, Boutros PC, Mason CE, De La Vega FM, Moore BL, Gonzalez-Porta M, Eberle MA, Tezak Z, Lababidi S, Truty R, Asimenos G, Funke B, Fleharty M, Chapman BA, Salit M, Zook JM; Global Alliance for Genomics and Health Benchmarking Team.

Nat Biotechnol. 2019 May;37(5):555-560. doi: 10.1038/s41587-019-0054-x. Epub 2019 Mar 11. Erratum in: Nat Biotechnol. 2019 Mar 21;:.

33.

The influence of BRCA2 mutation on localized prostate cancer.

Taylor RA, Fraser M, Rebello RJ, Boutros PC, Murphy DG, Bristow RG, Risbridger GP.

Nat Rev Urol. 2019 May;16(5):281-290. doi: 10.1038/s41585-019-0164-8. Review.

PMID:
30808988
34.

Widespread and Functional RNA Circularization in Localized Prostate Cancer.

Chen S, Huang V, Xu X, Livingstone J, Soares F, Jeon J, Zeng Y, Hua JT, Petricca J, Guo H, Wang M, Yousif F, Zhang Y, Donmez N, Ahmed M, Volik S, Lapuk A, Chua MLK, Heisler LE, Foucal A, Fox NS, Fraser M, Bhandari V, Shiah YJ, Guan J, Li J, Orain M, Picard V, Hovington H, Bergeron A, Lacombe L, Fradet Y, Têtu B, Liu S, Feng F, Wu X, Shao YW, Komor MA, Sahinalp C, Collins C, Hoogstrate Y, de Jong M, Fijneman RJA, Fei T, Jenster G, van der Kwast T, Bristow RG, Boutros PC, He HH.

Cell. 2019 Feb 7;176(4):831-843.e22. doi: 10.1016/j.cell.2019.01.025.

35.

Molecular Hallmarks of Multiparametric Magnetic Resonance Imaging Visibility in Prostate Cancer.

Houlahan KE, Salmasi A, Sadun TY, Pooli A, Felker ER, Livingstone J, Huang V, Raman SS, Ahuja P, Sisk AE Jr, Boutros PC, Reiter RE.

Eur Urol. 2019 Jul;76(1):18-23. doi: 10.1016/j.eururo.2018.12.036. Epub 2019 Jan 24.

PMID:
30685078
36.

BPG: Seamless, automated and interactive visualization of scientific data.

P'ng C, Green J, Chong LC, Waggott D, Prokopec SD, Shamsi M, Nguyen F, Mak DYF, Lam F, Albuquerque MA, Wu Y, Jung EH, Starmans MHW, Chan-Seng-Yue MA, Yao CQ, Liang B, Lalonde E, Haider S, Simone NA, Sendorek D, Chu KC, Moon NC, Fox NS, Grzadkowski MR, Harding NJ, Fung C, Murdoch AR, Houlahan KE, Wang J, Garcia DR, de Borja R, Sun RX, Lin X, Chen GM, Lu A, Shiah YJ, Zia A, Kearns R, Boutros PC.

BMC Bioinformatics. 2019 Jan 21;20(1):42. doi: 10.1186/s12859-019-2610-2.

37.

ONECUT2 is a driver of neuroendocrine prostate cancer.

Guo H, Ci X, Ahmed M, Hua JT, Soares F, Lin D, Puca L, Vosoughi A, Xue H, Li E, Su P, Chen S, Nguyen T, Liang Y, Zhang Y, Xu X, Xu J, Sheahan AV, Ba-Alawi W, Zhang S, Mahamud O, Vellanki RN, Gleave M, Bristow RG, Haibe-Kains B, Poirier JT, Rudin CM, Tsao MS, Wouters BG, Fazli L, Feng FY, Ellis L, van der Kwast T, Berlin A, Koritzinsky M, Boutros PC, Zoubeidi A, Beltran H, Wang Y, He HH.

Nat Commun. 2019 Jan 17;10(1):278. doi: 10.1038/s41467-018-08133-6.

38.

Molecular landmarks of tumor hypoxia across cancer types.

Bhandari V, Hoey C, Liu LY, Lalonde E, Ray J, Livingstone J, Lesurf R, Shiah YJ, Vujcic T, Huang X, Espiritu SMG, Heisler LE, Yousif F, Huang V, Yamaguchi TN, Yao CQ, Sabelnykova VY, Fraser M, Chua MLK, van der Kwast T, Liu SK, Boutros PC, Bristow RG.

Nat Genet. 2019 Feb;51(2):308-318. doi: 10.1038/s41588-018-0318-2. Epub 2019 Jan 14.

PMID:
30643250
39.

What Is Oligometastatic Prostate Cancer?

Fraser M, Koontz B, Emmenegger U, De Meerleer G, Khoo V, Feng F, Corcoran NM, Hovens CM, Tran PT, Ost P, Boutros PC; GAP6 Consortium.

Eur Urol Focus. 2019 Mar;5(2):159-161. doi: 10.1016/j.euf.2018.12.009. Epub 2019 Jan 12. Review.

PMID:
30642810
40.

Mutational analysis of head and neck squamous cell carcinoma stratified by smoking status.

Ghasemi F, Prokopec SD, MacNeil D, Mundi N, Gameiro SF, Howlett C, Stecho W, Plantinga P, Pinto N, Ruicci KM, Khan MI, Yoo J, Fung K, Sahovaler A, Palma DA, Winquist E, Mymryk JS, Barrett JW, Boutros PC, Nichols AC.

JCI Insight. 2019 Jan 10;4(1). pii: 123443. doi: 10.1172/jci.insight.123443. [Epub ahead of print]

41.

Molecular Evolution of Early-Onset Prostate Cancer Identifies Molecular Risk Markers and Clinical Trajectories.

Gerhauser C, Favero F, Risch T, Simon R, Feuerbach L, Assenov Y, Heckmann D, Sidiropoulos N, Waszak SM, Hübschmann D, Urbanucci A, Girma EG, Kuryshev V, Klimczak LJ, Saini N, Stütz AM, Weichenhan D, Böttcher LM, Toth R, Hendriksen JD, Koop C, Lutsik P, Matzk S, Warnatz HJ, Amstislavskiy V, Feuerstein C, Raeder B, Bogatyrova O, Schmitz EM, Hube-Magg C, Kluth M, Huland H, Graefen M, Lawerenz C, Henry GH, Yamaguchi TN, Malewska A, Meiners J, Schilling D, Reisinger E, Eils R, Schlesner M, Strand DW, Bristow RG, Boutros PC, von Kalle C, Gordenin D, Sültmann H, Brors B, Sauter G, Plass C, Yaspo ML, Korbel JO, Schlomm T, Weischenfeldt J.

Cancer Cell. 2018 Dec 10;34(6):996-1011.e8. doi: 10.1016/j.ccell.2018.10.016.

42.

A controlled trial of HNSCC patient-derived xenografts reveals broad efficacy of PI3Kα inhibition in controlling tumor growth.

Ruicci KM, Meens J, Sun RX, Rizzo G, Pinto N, Yoo J, Fung K, MacNeil D, Mymryk JS, Barrett JW, Boutros PC, Ailles L, Nichols AC.

Int J Cancer. 2019 Oct 15;145(8):2100-2106. doi: 10.1002/ijc.32009. Epub 2018 Dec 18. Erratum in: Int J Cancer. 2020 Jan 1;146(1):E23.

PMID:
30468243
43.

Pathway-based subnetworks enable cross-disease biomarker discovery.

Haider S, Yao CQ, Sabine VS, Grzadkowski M, Stimper V, Starmans MHW, Wang J, Nguyen F, Moon NC, Lin X, Drake C, Crozier CA, Brookes CL, van de Velde CJH, Hasenburg A, Kieback DG, Markopoulos CJ, Dirix LY, Seynaeve C, Rea DW, Kasprzyk A, Lambin P, Lio' P, Bartlett JMS, Boutros PC.

Nat Commun. 2018 Nov 12;9(1):4746. doi: 10.1038/s41467-018-07021-3.

44.

Lestaurtinib is a potent inhibitor of anaplastic thyroid cancer cell line models.

Pinto N, Prokopec SD, Vizeacoumar F, Searle K, Lowerison M, Ruicci KM, Yoo J, Fung K, MacNeil D, Lacefield JC, Leong HS, Mymryk JS, Barrett JW, Datti A, Boutros PC, Nichols AC.

PLoS One. 2018 Nov 12;13(11):e0207152. doi: 10.1371/journal.pone.0207152. eCollection 2018.

45.

MYC Protein Interactome Profiling Reveals Functionally Distinct Regions that Cooperate to Drive Tumorigenesis.

Kalkat M, Resetca D, Lourenco C, Chan PK, Wei Y, Shiah YJ, Vitkin N, Tong Y, Sunnerhagen M, Done SJ, Boutros PC, Raught B, Penn LZ.

Mol Cell. 2018 Dec 6;72(5):836-848.e7. doi: 10.1016/j.molcel.2018.09.031. Epub 2018 Nov 8.

46.

Combining accurate tumor genome simulation with crowdsourcing to benchmark somatic structural variant detection.

Lee AY, Ewing AD, Ellrott K, Hu Y, Houlahan KE, Bare JC, Espiritu SMG, Huang V, Dang K, Chong Z, Caloian C, Yamaguchi TN; ICGC-TCGA DREAM Somatic Mutation Calling Challenge Participants, Kellen MR, Chen K, Norman TC, Friend SH, Guinney J, Stolovitzky G, Haussler D, Margolin AA, Stuart JM, Boutros PC.

Genome Biol. 2018 Nov 6;19(1):188. doi: 10.1186/s13059-018-1539-5.

47.

A comparative study of survival models for breast cancer prognostication revisited: the benefits of multi-gene models.

Grzadkowski MR, Sendorek DH, P'ng C, Huang V, Boutros PC.

BMC Bioinformatics. 2018 Nov 3;19(1):400. doi: 10.1186/s12859-018-2430-9.

48.

MYC Interacts with the G9a Histone Methyltransferase to Drive Transcriptional Repression and Tumorigenesis.

Tu WB, Shiah YJ, Lourenco C, Mullen PJ, Dingar D, Redel C, Tamachi A, Ba-Alawi W, Aman A, Al-Awar R, Cescon DW, Haibe-Kains B, Arrowsmith CH, Raught B, Boutros PC, Penn LZ.

Cancer Cell. 2018 Oct 8;34(4):579-595.e8. doi: 10.1016/j.ccell.2018.09.001.

49.

Sex Differences in Cancer Driver Genes and Biomarkers.

Li CH, Haider S, Shiah YJ, Thai K, Boutros PC.

Cancer Res. 2018 Oct 1;78(19):5527-5537. doi: 10.1158/0008-5472.CAN-18-0362.

50.

Valection: design optimization for validation and verification studies.

Cooper CI, Yao D, Sendorek DH, Yamaguchi TN, P'ng C, Houlahan KE, Caloian C, Fraser M; SMC-DNA Challenge Participants, Ellrott K, Margolin AA, Bristow RG, Stuart JM, Boutros PC.

BMC Bioinformatics. 2018 Sep 25;19(1):339. doi: 10.1186/s12859-018-2391-z.

Supplemental Content

Loading ...
Support Center